Zug | Jotup

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

Retrieved on:

Mittwoch, November 3, 2021

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the third quarter ended September 30, 2021.

Key Points:

The third quarter marked significant progress across our portfolio, said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics.
Revenue: Total collaboration revenue was $0.3 million for the third quarter of 2021, compared to $0.1 million for the third quarter of 2020.
R&D Expenses: R&D expenses were $105.3 million for the third quarter of 2021, compared to $71.0 million for the third quarter of 2020.
CRISPR THERAPEUTICS word mark and design logo, CTX001, CTX110, CTX120, and CTX130 are trademarks and registered trademarks of CRISPR Therapeutics AG.

WISeKey’s WISeID Digital Identity Technology Now Allows Minting of Digital Identities NFTs in the Metaverse

Retrieved on:

Dienstag, November 2, 2021

The WISeKey NFT platform is secured by WISeKeys various security technologies enabling the authentication of digital identity based NFTs, physical objects as well as digital assets, in a safe end-to-end process.

Key Points:

The WISeKey NFT platform is secured by WISeKeys various security technologies enabling the authentication of digital identity based NFTs, physical objects as well as digital assets, in a safe end-to-end process.
As our digital lives become increasingly digitalized, Metaverse will leverage the advantages of the internet to establish a virtual world for its users.
The WISeKey WISeID NFTs minting process requires someone like Polygon, whose ultra-low transaction fees and PoS consensus mechanism are essential in meeting the demands of WISeKey's cybersecurity.
The WISeID second generation Digital Identities in Metaverse includes an identification module that its built into the protocol, while supplementary applications will be developed.

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on:

Dienstag, November 2, 2021

Technology, Bayer, Hemoglobinopathy, Investor, CRISPR Therapeutics, CRISPR, Vertex Pharmaceuticals, Company, CRSP, Degenerative disease, Cas9, Regenerative medicine, Nasdaq, Therapy, GLOBE, Gene editing, DNA, Fine chemical

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

Key Points:

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.
CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.
CRISPR THERAPEUTICS word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG.

Covis Significantly Strengthens Global Respiratory Portfolio Through Acquisition of Two Medicines from AstraZeneca

Retrieved on:

Montag, November 1, 2021

The addition of these medicines to Covis respiratory offering is a strong strategic complement to the companys existing therapeutic portfolio.

Key Points:

The addition of these medicines to Covis respiratory offering is a strong strategic complement to the companys existing therapeutic portfolio.
These medicines are used for the treatment of chronic obstructive pulmonary disease (COPD), which was the third leading cause of death worldwide in 2019.i
Building upon Covis previous acquisition of the global rights to respiratory medicines Alvesco, Omnaris and Zetonna from AstraZeneca in 2018, the companys expanded respiratory platform will create a continuum of care for respiratory patients.
This acquisition represents a highly strategic and synergistic transaction with AstraZeneca, enabling Covis tooffer a full continuum ofbest-in-class therapies for allergic rhinitis, asthma and COPD, said Covis CEO Michael Porter.
As a result of the acquisition, Covis is firmly placed as one of the top 10 respiratory companies in the world.

WISekey’s Founder and CEO Carlos Moreira was Interviewed by Steve Bannon on Warroom.org About The transHuman Code Bestseller Book and the Need to Humanize Technology

Retrieved on:

Freitag, Oktober 29, 2021

The pandemic has reinforced the importance of collaboration in the development, financing, and use of technology for our future.

Key Points:

The pandemic has reinforced the importance of collaboration in the development, financing, and use of technology for our future.
Organizing the wisdom and initiatives of technology innovators is essential so that everyone understands and stays at the forefront of The transHuman Codes mandate.
Mr. Moreira, noted, The book was published before the technology threat awareness movement, which is now underway, the importance of the conversation has only been accelerated and amplified.
One critical subplot to the global pandemic is that the very thing we hoped would save us technological innovation has fallen short.

RMRK Launches Unique NFT Project, Dino X Dino, on Its Kusama Based Platform Singular

Retrieved on:

Donnerstag, Oktober 28, 2021

Singular, Ethereum, NFT, Dino, Blockchain, Bird, Egg, Non-fungible token, Cryptocurrency, Wood-plastic composite, Communications satellite

RMRK Launches Unique NFT Project, Dino X Dino, on Its Kusama Based Platform Singular

Key Points:

RMRK Launches Unique NFT Project, Dino X Dino, on Its Kusama Based Platform Singular
Like RMRK's initial fundraise, Kanaria Dino x Dino is a project selling four tiers of NFT eggs that will hatch into fully customizable, composable dinosaurs intended for use in games and their corresponding metaverse.
The Dino x Dino project was developed in collaboration with RMRK's development team, and is the first such project on their increasingly popular NFT marketplace: Singular.
"When researching the ideal blockchain for the Dino X Dino launch, we connected with the RMRK team and chose them for many reasons, namely two.
RMRK Launches Unique NFT Project, Dino X Dino, on Its Kusama Based Platform Singular
Kanaria are multi-resource NFTs with different user-selectable outputs that can own, trade, and equip other compatible NFTs to alter their appearance and functionality.

WISeKey to Hold an Investor Day on December 13 at Nasdaq MarketSite

Retrieved on:

Mittwoch, Oktober 27, 2021

SIX Swiss Exchange, Technology, City, Fulcrum, NASDAQ, Big data, Semiconductor, WKEY, Internet, Computer, IOT, Artificial intelligence, Trust anchor, WIHN, AI, Cryptocurrency

WISeKey (NASDAQ: WKEY; SIX Swiss Exchange: WIHN) is a leading global cybersecurity company currently deploying large-scale digital identity ecosystems for people and objects using Blockchain, AI, and IoT respecting the Human as the Fulcrum of the Internet.

Key Points:

WISeKey (NASDAQ: WKEY; SIX Swiss Exchange: WIHN) is a leading global cybersecurity company currently deploying large-scale digital identity ecosystems for people and objects using Blockchain, AI, and IoT respecting the Human as the Fulcrum of the Internet.
WISeKey microprocessors secure the pervasive computing shaping todays Internet of Everything.
WISeKey IoT has an installed base of over 1.6 billion microchips in virtually all IoT sectors (connected cars, smart cities, drones, agricultural sensors, anti-counterfeiting, smart lighting, servers, computers, mobile phones, crypto tokens, etc.).
The WISeKey RoT serves as a common trust anchor to ensure the integrity of online transactions among objects and between objects and people.

WISeKey Launches its White-Label Trusted NFT Marketplace Platform Offering

Retrieved on:

Montag, Oktober 25, 2021

WISeKeys White-Label NFT Marketplace platform constantly monitors clients NFT marketplace and provides cybersecurity, identity management, marketing and support.

Key Points:

WISeKeys White-Label NFT Marketplace platform constantly monitors clients NFT marketplace and provides cybersecurity, identity management, marketing and support.
The White-Label WISeKey NFT Marketplace platform is similar to its WISe.ART marketplace platform, the only difference is that White-Label NFT Marketplace platform developed is readily available to use like plug and play upon demand, versus other traditional NFT marketplace platforms that require development of the whole platform from scratch, thus saving time and money to WISeKeys partners/clients.
The WISeKey NFT Marketplace platform, tested the appetite of the art and collectible community following a series of market tests starting in March of this year by selling high value NFTs, and incorporates the needs of this exclusive and high-volume marketplace.
Users all around the globe are gradually shifting towards white-label NFT marketplace platforms with strong security because they are easy, ready to use and most importantly, the white-label NFT marketplace development platform is cybersecurity tested and cost-effective.

WISeKey to introduce The Code to the Metaverse - Programming Our Future For Good at the forthcoming Vatican Collegio Teutonico meeting

Retrieved on:

Mittwoch, Oktober 20, 2021

David and Carlos have assembled a tremendous resource for understanding what this transHuman world will look like.

Key Points:

David and Carlos have assembled a tremendous resource for understanding what this transHuman world will look like.
''It is essential that as we navigate our way towards an uncertain future, that the best of humanity is strengthened and protected, and not irrevocably compromised.
''With the transHuman Code we can establish the most important basic principle of technological innovation - Ethics of use.
The WISeKey RoT serves as a common trust anchor to ensure the integrity of online transactions among objects and between objects and people.

nChain Appoints Hakan Yuksel as CEO

Retrieved on:

Mittwoch, Oktober 20, 2021

ZUG, Switzerland, Oct. 20, 2021 (GLOBE NEWSWIRE) -- nChain AG ("nChain" or "the Company") announced the appointment of Hakan Yuksel as Chief Executive Officer, based in the Company's Zug headquarters.He replaces Dr. David Washburn, who played an instrumental role in positioning the Company to deliver enterprise-grade data integrity solutions, and will remain in an advisory role for the coming months.

Key Points:

ZUG, Switzerland, Oct. 20, 2021 (GLOBE NEWSWIRE) -- nChain AG ("nChain" or "the Company") announced the appointment of Hakan Yuksel as Chief Executive Officer, based in the Company's Zug headquarters.He replaces Dr. David Washburn, who played an instrumental role in positioning the Company to deliver enterprise-grade data integrity solutions, and will remain in an advisory role for the coming months.
"I am extremely pleased to join nChain at this inflection point.Kensei provides a gateway to the BSV blockchain that addresses the technically tricky and challenging nature of building solutions on a blockchain.I am impressed by the depth of technical skills and knowledge within the Company, and look forward to broadening adoption of the BSV blockchain and driving the market for enterprise solutions," said Hakan Yuksel, CEO of nChain.
Founded in 2015, nChain advances the potential of blockchain technology through ongoing research and development of patentable inventions and by offering commercial solutions such as Kensei, a developer-friendly blockchain interface.
nChain also owns the CREA (business process management) and Equaleyes (mobile and web development) brands, which complement its core blockchain expertise.